Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow
Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow
Metastatic bone disease is an important prognostic factor for survival which will in median
 be close to two years after first diagnosis of osseous metastases. This open-label study will
 investigate the safety and efficacy of zoledronic acid in patients with breast cancer and
 minimal residual disease in the bone marrow.
Inclusion Criteria:

 -  Patients, with primary breast cancer who had undergone complete primary tumor
 resection and axillary lymph node dissection

 -  Evidence of minimal residual disease (disseminated tumor cells in bone marrow)

 -  Patients had to receive one of the following adjuvant therapy categories: chemotherapy
 ± hormonal therapy or hormonal therapy alone

 Exclusion Criteria:

 -  Inflammatory, metastatic or recurrent breast cancer or a history of breast cancer
 prior to the currently diagnosed case

 -  Neo-adjuvant chemotherapy, neo-adjuvant hormonal therapy, or neo-adjuvant radiotherapy

 -  Prior stem cell rescue/bone marrow transplant

 -  History of other cancers aside from non-melanomatous skin cancer or carcinoma in situ
 of the uterine cervix

 Additional protocol-defined inclusion / exclusion criteria may apply